Monday Lecture Series
Monday, November 9, 2015
4:00 p.m., Carson Family Auditorium (CRC)
Jeffrey V. Ravetch, M.D., Ph.D.
Theresa and Eugene M. Lang Professor and Head,
Laboratory of Molecular Genetics and Immunology,
The Rockefeller University
Diversification of antibody effector function
Recommended Readings
Empirical Articles
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014). Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell, 158(6), 1243-1253. doi: 10.1016/j.cell.2014.08.023
DiLillo, D. J., & Ravetch, J. V. (2015). Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell, 161(5), 1035-1045. doi:10.1016/j.cell.2015.04.016
Fiebiger, B. M., Maamary, J., Pincetic, A., & Ravetch, J. V. (2015). Protection in antibody-and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proceedings of the National Academy of Sciences, 112(18), E2385-E2394. doi:10.1073/pnas.1505292112
Wang, T. T., Maamary, J., Tan, G. S., Bournazos, S., Davis, C. W., Krammer, F., … & Ravetch, J. V. (2015). Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell, 162(1), 160-169. doi:10.1016/j.cell.2015.06.026
Review Papers
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2015). The role of Fc–FcγR interactions in IgG-mediated microbial neutralization. The Journal of Experimental Medicine, 212(9), 1361-1369. doi:10.1084/jem.20151267
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., … & Ravetch, J. V. (2014). Type I and type II Fc receptors regulate innate and adaptive immunity. Nature Immunology, 15(8), 707-716. doi:10.1038/ni.2939
